FTC Wades Into Health Care Reform, But Authorized Generics Likely On Sidelines
Executive Summary
For the third time in three weeks, the Federal Trade Commission has waded into the debate on health care reform with recommendations on competitive practices in the prescription drug market
You may also be interested in...
The Shadow Of 2003: Hatch/Waxman Changes May Join Health Reform Bills
The Medicare drug benefit, created in 2003, is casting a long shadow on the health care reform debate of 2009
The Shadow Of 2003: Hatch/Waxman Changes May Join Health Reform Bills
The Medicare drug benefit, created in 2003, is casting a long shadow on the health care reform debate of 2009
Follow-On Biologics Theatre: Next Act Is FDA
A House subcommittee hearing on FTC’s report on FOB competition includes yelling, a “challenge” to take an FOB product – and a promise from Chairman Pallone for more of the same.